Arguably the best-known test for evaluation of the anti-tumour immune response is the “Immunoscore”, developed by Galon et al.15,33 While the immune markers and cut points used to define categories have evolved during its development, it currently classifies tumours based on CD8+ and CD3+ cell density in the tumour centre and its invasive margin. Here, CD8A is linked to neoplasm.